Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma

Video

Alexander N. Shoushtari, MD, discusses the design of the ​phase 3 CheckMate-067 trial in advanced melanoma. 

Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the design of the ​phase 3 CheckMate-067 trial in advanced melanoma. 

​The study randomized ​patients with previously untreated, unresectable, stage III or IV melanoma 1:1:1 to receive 1 mg/kg of nivolumab (Opdivo) plus 3 mg/kg of ipilimumab (Yervoy) for 4 doses​, followed by 3 mg/kg of nivolumab​; 3 mg/kg of nivolumab plus ipilimumab-matched placebo; or 3 mg/kg of ipilimumab for 4 doses plus nivolumab-matched placebo until progression or unacceptable toxicity, says Shoushtari.

Less common subtypes, such as mucosal ​and acral melanoma, were included in the study, ​but the majority of patients had cutaneous melanoma, ​adds Shoushtari. Notably, patients with uveal melanoma ​were excluded. 

Ultimately, the trial was powered to detect a difference in progression-free survival and overall survival between nivolumab and ipilimumab​, as well as ​between the combination of nivolumab and ipilimumab and ipilimumab monotherapy, ​Shoushtari explains.

The difference in efficacy between nivolumab monotherapy and the combination regimen, as well as the long-term outcomes of patients with mucosal melanoma served as exploratory analyses of the study, Shoushtari concludes. 

Related Videos
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Michael J. Overman, MD
Jason Efstathiou, MD, DPhil
Amin Nassar, MD
Haeseong Park, MD, MPH
Matthew P. Goetz, MD
Phillip J. Koo, MD
Daniel Petrylak, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center